← All tickers

Is SRPT Worth Buying in 2026?

Sarepta Therapeutics,, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether Sarepta Therapeutics,, Inc. Common Stock (SRPT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 35 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.87% over 10 days); weak 1-year return of -59.8%; 3-month momentum negative (-10.7%). Currently 64.1% off its 52-week high. Score: -5/7.

Ready to act on this? 📈 Trade on Webull

SRPT is trading below its 200-day MA ($19.86) — a key warning sign the longer-term trend is under pressure. An RSI of 35.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -59.8% compares to +24.4% for SPY (trailed the market by 84.2%). The current 64.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $4,017 today
vs. S&P 500 (SPY) — same period trailed market by 84.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($19.86)
✗Above 50-day MA ($19.88)
✓RSI(14) neutral zone (30–70) — currently 35.0
✗Positive return (-59.8%)
!Within 10% of period high (−64.1%)
Period Range $15.75
$10.42 $43.92
RSI (14) 35.0
0 · OversoldOverbought · 100

Key Metrics

Price$15.75
Period Return-59.8%
Period High$43.92
Period Low$10.42
Drawdown−64.1%
MA-50$19.88
MA-200$19.86
RSI (14)35.0
Avg Volume (30d)3.0M
vs. SPYtrailed by 84.2%
Return Rank#1134 of 1245

Trade SRPT

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers